SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Whelan Jeremy S)
 

Sökning: WFRF:(Whelan Jeremy S) > High-Dose Chemother...

  • Dirksen, UtaUniversity Hospital Essen (författare)

High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases : Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008

  • Artikel/kapitelEngelska2019

Förlag, utgivningsår, omfång ...

  • 2019
  • 11 s.

Nummerbeteckningar

  • LIBRIS-ID:oai:lup.lub.lu.se:ffec299a-f80f-4af6-9a59-121343a8b9b9
  • https://lup.lub.lu.se/record/ffec299a-f80f-4af6-9a59-121343a8b9b9URI
  • https://doi.org/10.1200/JCO.19.00915DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:art swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • PURPOSE: The R2Pulm trial was conducted to evaluate the effect of busulfan-melphalan high-dose chemotherapy with autologous stem-cell rescue (BuMel) without whole-lung irradiation (WLI) on event-free survival (main end point) and overall survival, compared with standard chemotherapy with WLI in Ewing sarcoma (ES) presenting with pulmonary and/or pleural metastases. METHODS: From 2000 to 2015, we enrolled patients younger than 50 years of age with newly diagnosed ES and with only pulmonary or pleural metastases. Patients received chemotherapy with six courses of vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) and one course of vincristine, dactinomycin, and ifosfamide (VAI) before either BuMel or seven courses of VAI and WLI (VAI plus WLI) by randomized assignment. The analysis was conducted as intention to treat. The estimates of the hazard ratio (HR), 95% CI, and P value were corrected for the three previous interim analyses by the inverse normal method. RESULTS: Of 543 potentially eligible patients, 287 were randomly assigned to VAI plus WLI (n = 143) or BuMel (n = 144). Selected patients requiring radiotherapy to an axial primary site were excluded from randomization to avoid excess organ toxicity from interaction between radiotherapy and busulfan. Median follow-up was 8.1 years. We did not observe any significant difference in survival outcomes between treatment groups. Event-free survival was 50.6% versus 56.6% at 3 years and 43.1% versus 52.9% at 8 years, for VAI plus WLI and BuMel patients, respectively, resulting in an HR of 0.79 (95% CI, 0.56 to 1.10; P = .16). For overall survival, the HR was 1.00 (95% CI, 0.70 to 1.44; P = .99). Four patients died as a result of BuMel-related toxicity, and none died after VAI plus WLI. Significantly more patients in the BuMel arm experienced severe acute toxicities than in the VAI plus WLI arm. CONCLUSION: In ES with pulmonary or pleural metastases, there is no clear benefit from BuMel compared with conventional VAI plus WLI.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Brennan, BernadetteRoyal Manchester Children's Hospital (författare)
  • Le Deley, Marie CécileCentre Oscar Lambret,University of Paris-Saclay (författare)
  • Cozic, NathalieInstitut Gustave Roussy (författare)
  • van den Berg, HenkEmma Children’s Hospital,Academic Medical Center of University of Amsterdam (AMC) (författare)
  • Bhadri, VivekCancer Institute of New South Wales (författare)
  • Brichard, BénédicteSaint-Luc University Hospital (författare)
  • Claude, LineCentre Léon Bérard (författare)
  • Craft, AlanUniversity of Newcastle upon Tyne (författare)
  • Amler, SusanneUniversity of Münster,Friedrich Loeffler Institute (författare)
  • Gaspar, NatalieInstitut Gustave Roussy (författare)
  • Gelderblom, HansLeiden University Medical Centre (författare)
  • Goldsby, RobertUniversity of California, San Francisco,UCSF Benioff Children‘s Hospital (författare)
  • Gorlick, RichardUniversity of Texas (författare)
  • Grier, Holcombe E.Boston Children's Hospital (författare)
  • Guinbretiere, Jean MarcHôpital René-Huguenin (författare)
  • Hauser, PeterSemmelweis University (författare)
  • Hjorth, LarsLund University,Lunds universitet,Sena effekter efter barncancerbehandling,Forskargrupper vid Lunds universitet,Late effects after childhood cancer treatment,Lund University Research Groups(Swepub:lu)pedi-lhj (författare)
  • Janeway, KatherineBoston Children's Hospital (författare)
  • Juergens, HeribertUniversity Hospital Münster (författare)
  • Judson, IanRoyal Marsden NHS Foundation Trust (författare)
  • Krailo, MarkUniversity of Southern California (författare)
  • Kruseova, JarmilaCharles University in Prague (författare)
  • Kuehne, ThomasUniversity Children's Hospital, Basel (författare)
  • Ladenstein, RuthMedical University of Vienna (författare)
  • Lervat, CyrilCentre Oscar Lambret (författare)
  • Lessnick, Stephen L.Ohio State University (författare)
  • Lewis, IanUniversity of Leeds (författare)
  • Linassier, ClaudeUniversity Hospital of Tours (författare)
  • Marec-Berard, PerrinePediatric Hematology and Oncology Institute (IHOPE) (författare)
  • Marina, NeyssaFive Prime Therapeutics Inc (författare)
  • Morland, BruceBirmingham Children's Hospital (författare)
  • Pacquement, HélèneCurie Institute, Paris (författare)
  • Paulussen, MichaelWitten/Herdecke University (författare)
  • Randall, R. LorUniversity of California, Davis (författare)
  • Ranft, AndreasInstitut Gustave Roussy,University of Paris-Saclay (författare)
  • Le Teuff, GwénaëlUniversity of Birmingham (författare)
  • Wheatley, KeithUniversity College London Hospital (författare)
  • Whelan, JeremyThe Children's Hospital of Philadelphia,University of Pennsylvania (författare)
  • Womer, RichardSeattle Children’s Hospital (författare)
  • Oberlin, OdileInstitut Gustave Roussy (författare)
  • Hawkins, Douglas S.Children's Hospital and Regional Medical Center, Seattle,Seattle Children’s Hospital (författare)
  • University Hospital EssenRoyal Manchester Children's Hospital (creator_code:org_t)
  • Euro-E.W.I.N.G. 99 Investigators
  • Ewing 2008 Investigators

Sammanhörande titlar

  • Ingår i:Journal of Clinical Oncology37:34, s. 3192-32020732-183X

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy